Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).

Zhao J, Zhang Q, Chen S, Chen C, Yang C, Hua H, Wang T, Tang J, Zhang J, Yang Z, Yu J, Wei F, Song H, Cai S, Sun Q, Cao M, Li D

Open source

DOI: 10.1016/j.apsb.2026.05.027
Published: 2026 Jul
Container: Acta pharmaceutica Sinica. B
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.apsb.2026.05.027,
  title = {Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).},
  author = {Zhao J and Zhang Q and Chen S and Chen C and Yang C and Hua H and Wang T and Tang J and Zhang J and Yang Z and Yu J and Wei F and Song H and Cai S and Sun Q and Cao M and Li D},
  year = {2026},
  journal = {Acta pharmaceutica Sinica. B},
  doi = {10.1016/j.apsb.2026.05.027},
  url = {https://doi.org/10.1016/j.apsb.2026.05.027}
}

RIS

TY  - JOUR
TI  - Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).
AU  - Zhao J
AU  - Zhang Q
AU  - Chen S
AU  - Chen C
AU  - Yang C
AU  - Hua H
AU  - Wang T
AU  - Tang J
AU  - Zhang J
AU  - Yang Z
AU  - Yu J
AU  - Wei F
AU  - Song H
AU  - Cai S
AU  - Sun Q
AU  - Cao M
AU  - Li D
PY  - 2026
JO  - Acta pharmaceutica Sinica. B
DO  - 10.1016/j.apsb.2026.05.027
UR  - https://doi.org/10.1016/j.apsb.2026.05.027
ER  -

APA

J, Z., Q, Z., S, C., C, C., C, Y., H, H., T, W., J, T., J, Z., Z, Y., J, Y., F, W., H, S., S, C., Q, S., M, C., & D, L. (2026). Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).. Acta pharmaceutica Sinica. B. https://doi.org/10.1016/j.apsb.2026.05.027

Source records

pubmed · retrieved 2026-09-27T00:08:35.387Z